Versant Ventures Launches Bright Peak Therapeutics

Versant Ventures Launches Bright Peak Therapeutics
/

BASEL, Switzerland & SAN DIEGO–(BUSINESS WIRE)–Versant Ventures today announced the debut of Bright Peak Therapeutics, a biotechnology company developing a platform to chemically synthesize and optimize the structure and function of proteins. Versant has made a $35 million Series A commitment to the company, which was launched out of the firm’s Ridgeline Therapeutics Discovery Engine based in Basel, Switzerland. Bright Peak’s technology platform, licensed from ETH Zürich, allows a wide range